Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
Centogene will help Aldeyra identify patients with Sjögren-Larsson Syndrome, a rare genetic disease for which Aldeyra is developing a treatment.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Under a new agreement, Centogene will integrate its CentoMD database of phenotype/genotype variants of rare diseases into the Qiagen bioinformatics platform.
Centogene said it will use the funds to accelerate growth and expansion in the areas of genetic testing, pharmaceutical collaborations, and big-data solutions.
The partners will work to offer panel-based genetic characterization for a US-based cohort.
The company has installed Illumina's HiSeq X sequencing platform and expects to sequence 20,000 genomes by the end of next year.
The two companies plan to join their respective technologies in order to help clinicians better interpret genetic variant data.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.